Biotech Company Eradivir is Developing Lead Drug EV25 to Treat Influenza
July 10, 2024
July 10, 2024
WEST LAFAYETTE, Indiana, July 10 -- Purdue University issued the following news release:
* * *
Company has completed the required preclinical studies and will seek regulatory approval to dose volunteers in Belgium by the end of the year
* * *
Eradivir, a preclinical biotech company, leverages small molecule targeting technology developed in Philip Low's lab at Purdue University to focus on a platform of immunotherapies for viral infections . . .
* * *
Company has completed the required preclinical studies and will seek regulatory approval to dose volunteers in Belgium by the end of the year
* * *
Eradivir, a preclinical biotech company, leverages small molecule targeting technology developed in Philip Low's lab at Purdue University to focus on a platform of immunotherapies for viral infections . . .